| 2026-08-04 | Document | IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-07-31 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-27 | Press release | IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monothe |
| 2026-07-17 | Press release | IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs |
| 2026-06-26 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-17 | Press release | IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors |
| 2026-06-15 | Press release | IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Cl |
| 2026-06-10 | Press release | IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Share |
| 2026-06-08 | Press release | IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 2026-06-08 | Press release | IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants |
| 2026-06-03 | Press release | IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer |
| 2026-06-01 | Press release | IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib |
| 2026-05-31 | Presentation | https://ir.ideayabio.com/image/OptimUM-02+ASCO+-+26MAY2026.pdf |
| 2026-05-29 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-26 | Press release | IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference |
| 2026-05-05 | Document | IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-04 | Presentation | Download PDF |
| 2026-05-01 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-30 | Press release | IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology |
| 2026-04-21 | Press release | IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2 |
| 2026-04-13 | Press release | IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Dar |
| 2026-04-13 | Presentation | https://ir.ideayabio.com/image/20260413_OptimUM02_ToplineWebcast_vFinal.pdf |
| 2026-04-10 | Press release | IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, A |
| 2026-04-06 | Press release | IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of |
| 2026-03-30 | Press release | IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG I |
| 2026-03-27 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-22 | Press release | IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 O |
| 2026-03-18 | Press release | IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs |
| 2026-03-09 | Press release | IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for |
| 2026-02-27 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-25 | Press release | IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecif |
| 2026-02-23 | Press release | IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer |
| 2026-02-17 | Document | IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update |
| 2026-01-30 | Press release | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-11 | Press release | IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Heal |
| 2026-01-05 | Press release | IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-11 | Press release | IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib |
| 2025-11-04 | Document | IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 2025-08-05 | Document | IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 2025-05-06 | Document | IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update |